metaLead AG joins BaseLaunch portfolio

metaLead Therapeutics AG, a spin-out from the University of Zurich, is proud to announce its inclusion in BaseLaunch, a leading biotech venture accelerator. This partnership marks a significant milestone in metaLead’s journey to revolutionize the treatment of metal-related diseases, with a particular focus on Wilson disease.

Wilson disease is a rare genetic disorder characterized by impaired copper metabolism, leading to severe neurological and hepatic complications. Current treatments often fall short, leaving patients with persistent unmet medical needs. metaLead is committed to addressing these challenges through its proprietary drug development platform, which leverages expertise in metal-binding peptides and chelation chemistry to develop targeted, effective therapies.

BaseLaunch’s support includes funding, access to a network of biotech experts, and strategic guidance, all of which will be instrumental in advancing metaLead’s Wilson disease program. This innovative therapy aims to significantly improve outcomes for Wilson disease patients suffering from neurological manifestations.

"We are excited to join the BaseLaunch ecosystem," said Dr. Michal Shoshan, CEO of metaLead Therapeutics AG. "This partnership provides us with the resources and mentorship needed to accelerate the development of our novel therapies and bring hope to patients with unmet medical needs."

With the backing of BaseLaunch, metaLead is poised to advance its mission of pioneering solutions for metal-related diseases, pushing the boundaries of innovation in therapeutic development.